Cellectar Biosciences is a biotechnology business based in the US. Cellectar Biosciences shares (CLRB) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectar Biosciences employs 20 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.37 |
|---|---|
| 52-week range | $1.56 - $4.45 |
| 50-day moving average | $2.87 |
| 200-day moving average | $3.06 |
| Wall St. target price | $12.60 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.09 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.365 from 2024-07-25
| 1 week (2024-07-19) | -6.15% |
|---|---|
| 1 month (2024-06-27) | 1.50% |
| 3 months (2024-04-26) | -21.95% |
| 6 months (2024-01-26) | -36.93% |
| 1 year (2023-07-27) | 25.13% |
|---|---|
| 2 years (2022-07-27) | -44.74% |
| 3 years (2021-07-27) | 118.98% |
| 5 years (2019-07-26) | 10.00% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -91.47% |
| Return on equity TTM | -304.38% |
| Profit margin | 0% |
| Book value | $0.27 |
| Market Capitalization | $90.3 million |
TTM: trailing 12 months
We're not expecting Cellectar Biosciences to pay a dividend over the next 12 months.
Cellectar Biosciences's shares were split on a 1:10 basis on 21 July 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellectar Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cellectar Biosciences shares which in turn could have impacted Cellectar Biosciences's share price.
Over the last 12 months, Cellectar Biosciences's shares have ranged in value from as little as $1.5602 up to $4.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectar Biosciences's is 0.986. This would suggest that Cellectar Biosciences's shares are less volatile than average (for this exchange).
Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. .
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.